Samsung Bioepis gets nod for sale of ophthalmology biosimilar drug in Europe
Aug 23, 2021
South Korean biopharmaceutical firm Samsung Bioepis Co. said Monday it has won approval from European authorities for the sale of its ophthalmology biosimilar, Byooviz. The European Commission granted the marketing authorization on ranibizumab biosimilar, previously known as SB11, which references Swiss pharmaceutical giant Novartis' blockbuster medication Lucentis. It is the first biosimilar referencing Lucentis to be commercialized in the European Union. The Novartis product registered $1.93